FDA has issued regulations governing IND products to protect human subjects enrolled in clinical trials. For example, in 21 CFR part 312, sponsors must submit chemistry, manufacturing and control (CMC) information on a drug or biological product as part of an IND application (§ 312.23(a)(7)).
cGMP: Strategies for Implementation and Compliance for Phase I Investigational Drug and Biologic Products - Webinar by GlobalCompliancePanel
9 January 2014, Fremont, United States
Introduction
Venue
Online Training
Online Training, 161 Mission Falls Lane, Suite 216, Fremont, 94539, United States
Useful links
Organised by
GlobalCompliancePanel
Contact information
Mr John Robinson
161 Mission Falls Lane, Suite 216, Fremont, 94539, United States of America
8004479407
Contact us by email
161 Mission Falls Lane, Suite 216, Fremont, 94539, United States of America
8004479407
Contact us by email
Related events
New Zealand Institute of 91AV Conference 2024 (NZIC-24)
24 November 2024 14:00 - 28 November 2024 14:00, Dunedin, New Zealand
Drugging the Multimorbidity Associated with Ageing
17 January 2025 09:30-17:00, London, United Kingdom
Future Labs Live Basel
27 May 2025 09:00 - 28 May 2025 17:00, Basel, Switzerland
European Glycoscience Community Webinar Series
25 January 2024 15:00 - 19 December 2024 18:00
Search
Advertisement
Spotlight
Explore
Membership
